1.
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable st...
by Stein, Evan A, Prof, Dr
The Lancet (British edition), 2012, Vol.380 (9836), p.29-36
2.
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controll...
by Baigent, Colin, Prof
The Lancet (British edition), 2011, Vol.377 (9784), p.2181-2192
3.
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LA...
by Giugliano, Robert P, Dr
The Lancet (British edition), 2012, Vol.380 (9858), p.2007-2017
4.
Into the future: diversifying lipid management
by Tonkin, Andrew M
The Lancet (British edition), 2012, Vol.380 (9858), p.1971-1974
5.
Inhibition of PCSK9 in familial hypercholesterolaemia
by Sijbrands, Eric JG
The Lancet (British edition), 2012, Vol.380 (9836), p.6-7
6.
SHARP: a stab in the right direction in chronic kidney disease
by Stevens, Kathryn K
The Lancet (British edition), 2011, Vol.377 (9784), p.2153-2154
